SCHEMBL1903512

SCHEMBL1903512

CCNc1cccc(C)c1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.50
FABP4 P15090 3/20 0.49
FABP3 P05413 1/20 0.49
TRPM4 Q8TD43 1/20 0.47
TDP1 Q9NUW8 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PTGS2 P35354 3/20 0.42
HPGD P15428 3/20 0.42
CYP3A4 P08684 2/20 0.42
AKR1B10 O60218 1/20 0.42
TRPA1 O75762 1/20 0.42
ABCB11 O95342 1/20 0.42
DHFR P00374 1/20 0.42
LMNA P02545 1/20 0.42
MPO P05164 1/20 0.42
CYP1A2 P05177 1/20 0.42
CHRM1 P11229 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5264765 0.84 ALDH1A1 (0.41) KDM4EMEN1KMT2AHPGDCYP3A4
SCHEMBL4607469 0.84 KDM4E (0.49) KDM4EFABP4FABP3TRPM4TDP1
SCHEMBL16181442 0.82 FABP4 (0.50) KDM4EFABP4TDP1L3MBTL1MEN1
SCHEMBL20999136 0.82 CA12 (0.55) KDM4EMEN1KMT2AHPGDALDH1A1
SCHEMBL8009873 0.81 KDM4E (0.54) KDM4EFABP4FABP3TRPM4L3MBTL1
SCHEMBL28030166 0.81 KDM4E (0.47) KDM4EFABP4FABP3TRPM4TDP1
SCHEMBL22904377 0.81 ALDH1A1 (0.41) KDM4EFABP4L3MBTL1MEN1KMT2A
SCHEMBL13921287 0.81 PLK1 (0.59) KDM4EFABP4TDP1MEN1KMT2A
SCHEMBL6497268 0.80 ITGB3 (0.53) KDM4EFABP4FABP3TRPM4MEN1
SCHEMBL16318050 0.79 KDM4E (0.54) KDM4EFABP4FABP3TRPM4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633160-B2 Small molecule inhibitors of PDZ interactions NONO INC. (CA) 2014-01-21 US disclosed
US-7935825-B2 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain ALLERGAN, INC. (US) 2011-05-03 US disclosed
EP-1436264-B9 ARYLSULFANYL AND HETEROARYLSULFANYL DERIVATIVES FOR TREATING PAIN ALLERGAN INC (US) 2009-05-06 EP disclosed
US-20090062213-A1 Small Molecule Inhibitors of PDZ Interactions ARBOR VITA CORPORATION (US) 2009-03-05 US disclosed
EP-1436264-B1 ARYLSULFANYL AND HETEROARYLSULFANYL DERIVATIVES FOR TREATING PAIN ALLERGAN INC (US) 2008-12-31 EP disclosed
US-20070219255-A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain BURK ROBERT M 2007-09-20 US disclosed
US-7214678-B2 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain ALLERGAN, INC. (US) 2007-05-08 US disclosed
US-20060217349-A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain ALLERGAN, INC. 2006-09-28 US disclosed
US-7098223-B2 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20050032746-A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain ALLERGAN, INC. 2005-02-10 US disclosed
US-6825221-B2 PROSTAGLANDIN INHIBITORS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS, POST-OPERATIVE PAIN, PAIN ASSOCIATED WITH DENTAL ALLERGAN, INC. 2004-11-30 US disclosed
EP-1436264-A1 ARYLSULFANYL AND HETEROARYLSULFANYL DERIVATIVES FOR TREATING PAIN Allergan, Inc. (US) 2004-07-14 EP disclosed
US-20030078236-A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain ALLERGAN, INC. 2003-04-24 US disclosed
WO-2003033470-A1 ARYLSULFANYL AND HETEROARYLSULFANYL DERIVATIVES FOR TREATING PAIN ALLERGAN, INC. (US) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062213-A1 Small Molecule Inhibitors of PDZ Interactions PDLIM5, DAB2IP, PSD KDM4E 4235/4885FABP4 1041/4885FABP3 153/4885
US-20070219255-A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain OPRL1, OPRK1, OPRD1 KDM4E 1642/4885FABP4 3119/4885FABP3 3711/4885
US-20050032746-A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain OPRL1, OPRK1, OPRD1 KDM4E 1642/4885FABP4 3119/4885FABP3 3711/4885
US-20030078236-A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain OPRD1, OPRK1, OPRL1 KDM4E 2236/4885FABP4 3124/4885FABP3 3518/4885
US-20060217349-A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain OPRL1, OPRK1, OPRD1 KDM4E 1642/4885FABP4 3119/4885FABP3 3711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.